Saltar al contenido
MilliporeSigma
Todas las fotos(1)

Documentos

AP101P

Sigma-Aldrich

Rabbit Anti-Human IgG Antibody, HRP conjugate

Chemicon®, from rabbit

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.46

biological source

rabbit

Quality Level

100

conjugate

peroxidase conjugate

antibody form

F(ab′)2 fragment of affinity isolated antibody

antibody product type

secondary antibodies

clone

polyclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
western blot: suitable

shipped in

wet ice

target post-translational modification

unmodified

Categorías relacionadas

Application

Detect Human IgG using this Rabbit anti-Human IgG Antibody, HRP conjugate validated for use in ELISA & WB.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Herramienta de selección de productos.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Bibek Parajuli et al.
Biochemistry, 55(44), 6100-6114 (2016-10-13)
We recently reported the discovery of a recombinant chimera, denoted DAVEI (dual-acting virucidal entry inhibitor), which is able to selectively cause specific and potent lytic inactivation of both pseudotyped and fully infectious human immunodeficiency virus (HIV-1) virions. The chimera is
Kasopefoluwa Y Oguntuyo et al.
mBio, 12(1) (2021-02-18)
The global coronavirus disease 2019 (COVID-19) pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent-phase plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Ghadeer Alhamar et al.
The Journal of clinical endocrinology and metabolism, 108(7), e474-e479 (2023-01-08)
Poor glucose control has been associated with increased mortality in COVID-19 patients with type 1 diabetes (T1D). This work aimed to assess the effect of prevaccination glucose control on antibody response to the SARS-CoV-2 vaccine BNT162b2 in T1D. We studied
Bibek Parajuli et al.
The Biochemical journal, 475(5), 931-957 (2018-01-19)
We previously reported a first-generation recombinant DAVEI construct, a dual action virus entry inhibitor composed of cyanovirin-N (CVN) fused to a membrane proximal external region or its derivative peptide Trp3. DAVEI exhibits potent and irreversible inactivation of HIV-1 (human immunodeficiency
Kasopefoluwa Y Oguntuyo et al.
medRxiv : the preprint server for health sciences (2020-08-21)
The global COVID-19 pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the SARS-CoV-2 spike glycoprotein (CoV2-S). However, rigorous efficacy testing requires extensive
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico